Authors

Nastaran Foyouzi, M.D., Marcelle I. Cedars, M.D., Heather G. Huddleston, M.D.

Vol 98, Issue 1 , Pages 151-155.e3

Abstract

Objective:

To compare the cost of two strategies for managing the patient with recurrent pregnancy loss (RPL).

Design:

Cost analysis using a decision analytic model was used to compare obtaining an evidence-based workup (EBW) for RPL versus obtaining a karyotype of the products of conception (POC) and proceeding with an EBW only in the setting of euploid POC.

Setting:

Outpatient care.

Patient(s):

A simulated cohort of patients experiencing a second pregnancy loss.

Intervention(s):

Not applicable.

Main Outcome Measure(s):

Total cost of investigating the cause of RPL after a second pregnancy loss.

Result(s):

For all age categories, obtaining a karyotype of POC was less costly than an evidenced-based RPL evaluation. Monte Caro analysis demonstrated a net economic benefit for the karyotype strategy ($4,498 [±$792] vs. $5,022 [±$1,130]).

Conclusion(s):

Our model suggests an economic advantage for obtaining a karyotype of POC in women with second miscarriage.

Read the full text at: http://www.fertstert.org/article/S0015-0282(12)00438-4/fulltext